.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
US Department of Justice
Accenture
Moodys
Harvard Business School
Citi
QuintilesIMS
Mallinckrodt
Fish and Richardson
McKesson

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020478

« Back to Dashboard

NDA 020478 describes ULTANE, which is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the ULTANE profile page.

The generic ingredient in ULTANE is sevoflurane. There are five drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the sevoflurane profile page.

Summary for 020478

Tradename:1
Applicant:1
Ingredient:1
Patents:4
Formulation / Manufacturing:see details

Pharmacology for NDA: 020478

Physiological EffectGeneral Anesthesia

Suppliers and Packaging for NDA: 020478

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ULTANE sevoflurane LIQUID;INHALATION 020478 NDA AbbVie Inc. 0074-4456 0074-4456-04 250 mL in 1 BOTTLE, PLASTIC (0074-4456-04)
ULTANE sevoflurane LIQUID;INHALATION 020478 NDA AbbVie Inc. 0074-4456 0074-4456-51 250 mL in 1 BOTTLE, PLASTIC (0074-4456-51)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:LIQUID;INHALATIONStrength100%
Approval Date:Jun 7, 1995TE:ANRLD:Yes
Patent:► SubscribePatent Expiration:Jul 27, 2017Product Flag?Substance Flag?Delist Request?Y
Patent:► SubscribePatent Expiration:Jul 9, 2018Product Flag?Substance Flag?Delist Request?Y
Patent:► SubscribePatent Expiration:Jul 27, 2017Product Flag?Substance Flag?Delist Request?Y

Expired Orange Book Patents for NDA: 020478

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
AbbvieULTANEsevofluraneLIQUID;INHALATION020478-001Jun 7, 1995► Subscribe► Subscribe
AbbvieULTANEsevofluraneLIQUID;INHALATION020478-001Jun 7, 1995► Subscribe► Subscribe
AbbvieULTANEsevofluraneLIQUID;INHALATION020478-001Jun 7, 1995► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Mallinckrodt
Fuji
Federal Trade Commission
UBS
Chinese Patent Office
Citi
Fish and Richardson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot